CNVY

ANALYST NOTE: CNVY (Convey Health Solutions Holdings, Inc.) Date: 2026-06-13 Current Price: $10.51

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 0.6% (Sub-threshold)

Analysis: As of the close on 2026-06-13, the structural setup for CNVY is not defined. The provided data indicates a "context-only" state with no active, forming, or invalidated coil structure recorded.

• Volatility Context: The current ATR of 0.6% is significantly below the StoryStocks canonical "high" (4–6%) or "sweet spot" range, indicating sub-threshold volatility. This suggests the stock is currently in a low-activity consolidation or a state where the structural parameters required to define a "coil" (run-up, pullback, and defined support levels) have not yet materialized or been recorded in the system.

2. Thesis Layer

Thesis Status: TACTICAL / SETUP-LED Macro Thesis: None.

There is no named secular thesis attached to CNVY as of this date. The investment case is strictly tactical and dependent on the quality of the technical setup and immediate business fundamentals. No macroeconomic tailwinds or sector-specific secular themes are currently driving the conviction stack. The analysis must rely entirely on the structural readiness of the chart and the verifiable operational data from the company's recent filings.

3. Business Overview

Company: Convey Health Solutions Holdings, Inc. (CNVY) Industry: Healthcare Services / Technology Business Model: The company operates a hybrid model combining sophisticated technology platforms with expert consulting services to optimize operational workflows for healthcare clients.

Operational Segments:

• Technology Enabled Solutions: Offers adaptable, web-based applications used to identify, monitor, and manage contractual services and benefits for Medicare and Medicaid beneficiaries.
• Advisory Services: Provides strategic guidance including sales/marketing strategy, provider network design, regulatory compliance, star rating enhancement, clinical practice refinement, pharmacy operations management, and risk adjustment methodologies.

Client Base: The company serves government-sponsored health programs, Medicare Advantage organizations, general Medicare providers, and Pharmacy Benefit Managers (PBMs).

Historical Performance (Source: Q1 2022 Earnings Transcript, 2022-05-14):

• Revenue: Reported net revenues of $96.7 million for Q1 2022, a 17% increase year-over-year.
• Profitability: Adjusted EBITDA was $15.3 million, in line with expectations. Management indicated an expectation for the balance of 2022 to have higher margins than Q1.
• Segment Growth: The Technology Enabled Solutions segment generated $83.2 million in revenue, a 20% increase over the prior year, driven by growth in supplemental benefit services and health plan management.
• Customer Concentration: The largest customer accounted for 28% of total revenue (up 400 bps), while the fee from this customer decreased by 300 bps to 17% of revenue.
• Guidance: As of May 14, 2022, management stated they were not changing their guidance for 2022 and believed the 2023 selling season was off to a good start.

*Note: The evidence base for the business model is anchored in 2022 data. No financial updates, earnings transcripts, or operational metrics from the period between 2022 and the event date of 2026-06-13 are available in the provided evidence block.*

4. Archetype and Conviction

Archetype Candidate: — Classification: Unable to classify due to missing structural data.

Conviction Stack Analysis:

• Thesis Strength: Low. No macro or secular thesis is present.
• Evidence Quality: Mixed. The business fundamentals are well-documented for the 2022 period (strong growth, margin expansion expectations), but there is a critical gap in evidence for the 2023–2026 period. The current price of $10.51 cannot be contextualized against current earnings or guidance without post-2022 data.
• Structural Quality: Weak/Unknown. The ATR of 0.6% indicates a lack of volatility required to form a high-conviction setup. The "sub-threshold" volatility suggests the market is not currently pricing in significant directional moves or that the stock is in a dormant phase.
• Rerating Potential: Unknown. Without current earnings data or a defined technical breakout, the potential for a rerating cannot be assessed.

Summary: The name is currently a "context-only" observation. While the 2022 operational data suggests a healthy business model with recurring revenue characteristics, the lack of recent financial updates and the absence of a defined technical setup prevent any classification as a growth leader, value recovery, or defensive operator at this specific moment.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Fundamental: Release of earnings data or guidance updates for 2023, 2024, 2025, or 2026 confirming the continuation of the growth trajectory and margin expansion observed in 2022.

What Would Invalidate the Case:

• Fundamental: Evidence of significant customer churn, margin compression, or a failure to meet the 2022 guidance (if applicable to the current period).

Critical Gaps in Evidence:

• Temporal Gap: The most significant gap is the lack of any financial or operational data between May 2022 and June 2026. The current price of $10.51 cannot be evaluated against current fundamentals without this data.
• Sector Context: No specific sector classification or industry peer comparison data is available for the 2026 timeframe.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key risks: 1) The 4-year gap in financial data may hide significant deterioration in the business model. 2) Lack of volatility may result in prolonged capital inefficiency. 3) Absence of a defined entry/exit structure prevents risk management. Sizing hint: N/A (Position size should be zero until a setup forms). Expected path: The stock will likely remain in a low-volatility consolidation until a catalyst (earnings release or technical breakout) defines a new structural baseline. Expected horizon: Indefinite until structural parameters are established. Failure mode to watch: A confirmed close below any potential support level if a structure were to form, or the discovery of negative fundamental news filling the 2022-2026 data gap.